RESUMO
This study evaluated the humoral response to protein components of the Cuban-produced vaccine against serogroups B and C meningococcus, VA-MENGOC-BC, in adults and children 1 to 5 years old. The trial was conducted in an area of the Department of Antioquia, Colombia, in which an elevated incidence of meningococcal disease had been recorded. The serum anti-vaccine-protein response was studied before (T0) and after (T1) vaccination by means of enzyme-linked immunosorbent assay (ELISA), and lytic capacity was evaluated through the bactericidal antibodies test (BAT). The ELISA was performed before and after vaccination on the sera of 407 adults and 213 children. Lytic capacity against Cuban meningococcal strain B:4:P1.15 was studied with BAT in paired sera from 90 adults and 114 children. The two techniques showed a statistically significant response (P < 0.01) to the vaccine, in both adults and children. Of the total number of subjects tested with ELISA, 81% showed an immune response to the vaccine (T1/T0 > or = 2) (95% confidence interval, CI95%: 78% to 84%); among children, immune response was 91% (CI95%: 87% to 94%). All the children 1 year of age (n = 7) responded. Seroconversion (T1/T0 > or = 4), as shown by ELISA, was 80% among adults (CI95%: 73% to 86%) and 90% among children (CI95%: 83% to 100%). BAT demonstrated seroconversion in 85% (CI95%: 78% to 92%) of subjects who had been seronegative before vaccination, 85% of the adults (CI95%: 76% to 95%) and 84% of the children (CI95%: 72% to 96%). Seroconversion among children 3 and 4 years of age was 80%. The group of sera from children 1, 2, and 5 years old available for study with BAT was too small for meaningful statistical analysis; all of them seroconverted. In 20 sera chosen randomly for study of their bactericidal activity against all the strains isolated from patients in Colombia (B:4:P1.15, B:8:P1.nt, and two strains of serogroup C), seroconversion was found in all 20 cases. These results give reason to think that vaccination in this group produced an effective immune response, as measured serologically, and this belief is corroborated in practice by the lack of any cases of meningococcal disease through September 1994 among the people vaccinated.
Assuntos
Anticorpos Antibacterianos/biossíntese , Proteínas de Bactérias/imunologia , Vacinas Bacterianas/imunologia , Neisseria meningitidis/imunologia , Adulto , Pré-Escolar , Colômbia , Intervalos de Confiança , Feminino , Humanos , Lactente , Masculino , Vacinas Meningocócicas , Pessoa de Meia-Idade , Neisseria meningitidis/classificação , SorotipagemRESUMO
As a complement to studying humoral immune response to the proteins of an antimeningococcal vaccine (VA-MENGOC-BC) against serogroups B and C, the humoral immune response to polysaccharide C of the vaccine was also evaluated in 142 children from 1 to 5 years of age in an area of the Department of Antioquia, Colombia. Paired pre-(T0) and post-vaccination (T1) sera were tested for IgG response by means of ELISA and for serum lytic capacity against a strain of serogroup C by means of the bactericidal antibodies test (BAT). Response to the vaccine was statistically significant (P < 0.01) by both techniques. PAB demonstrated seroconversion (T1/T0 > or = 4) in 88% (95% confidence interval, CI95%: 80% to 95%) of all those who were seronegative before vaccination. The proportion of seroconversion in children 2, 3, and 4 years of age was 86% or more. Of all the sera tested with ELISA, 93% (CI95%: 89% to 97%) showed response to the vaccine (T1/T0 > or = 2), and 98% (CI95%: 94% to 100%) of the subjects with T0 < or = 500 U/mL seroconverted. In this sample, the vaccine stimulated a specific and protective response as measured by ELISA and BAT, the latter test being utilized to evaluate protection status.
Assuntos
Anticorpos Antibacterianos/biossíntese , Cápsulas Bacterianas/imunologia , Vacinas Bacterianas/imunologia , Neisseria meningitidis/imunologia , Polissacarídeos Bacterianos/imunologia , Pré-Escolar , Colômbia , Intervalos de Confiança , Humanos , Lactente , Vacinas Meningocócicas , Neisseria meningitidis/classificação , SorotipagemRESUMO
Los portadores asintomáticos constituyen reservorios importantes del virus de la hepatitis B, a pesar de lo cual no se han reportado hasta el momento ensayos terapéuticos en estos grupos. Por constituir, además, un modelo que permite evaluar las bondades de los antivirales junto a los antecedentes del empleo de la vía intraperitoneal en trabajos anteriores realizados en nuestro medio, hemos empleado esta vía para administrar IFN en concentraciones crecientes a 15 portadores asintomáticos a los que no se les detectó actividad de IFN circulante antes de iniciar la experiencia. Se estudiaron el número total de partículas, partículas de Dane, antígeno de superficie del virus de la hepatitis B (HBsAg) y antígeno "e" (HBeAg). Las variaciones encontradas en estos indicadores denotan que se alcanzó el estado antiviral con los tres esquemas empleados. A pesar de las limitaciones del tamaño de la muestra, se observaron las mayores modificaciones al mes postratamiento en el grupo al cual se administró la dosis más elevada, pudiendo clasificarse la evolución de algunos de los tratados como de tipo II. La ausencia de toxicidad y complicaciones validan el fármaco y la vía empleada para nuevos ensayos tendientes a lograr un esquema terapéutico racional, determinante dosis, periodicidad y duración del tratamiento